Vanguard Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Vanguard Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-29,905	Closed	-$1M	–	2479
2026 Q1	$1M	Buy	+29,905	New	+$1.17M	﹤0.01%	1788

Vanguard Asset Management's SLNO Position: Q2 2026 in Review

Vanguard Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 29,905 shares — an estimated $1M sold.

Vanguard Asset Management first reported a position in SLNO in Q1 2026 and held it in 1 quarter. The position peaked at $1M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Vanguard Asset Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Vanguard Asset Management sold 29,905 Soleno Therapeutics shares in Q2 2026, an estimated $1M.
Vanguard Asset Management first reported a position in Soleno Therapeutics in Q1 2026 and held it in 1 quarter.
Vanguard Asset Management's Soleno Therapeutics position peaked at $1M in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.